C-Path has partnered with Parkinson’s UK, the world’s largest patient-led charity for Parkinson’s disease, to lead the Critical Path for Parkinson’s (CPP), a global collaboration that promises to accelerate the path to new treatments for PD. By facilitating collaboration among scientists from the biopharmaceutical industry, academic institutions, government agencies, patient-advocacy organizations, and other key stakeholders, CPP fosters innovative collaborative research to increase efficiency, safety, and speed in developing new therapies.
|World Health Organization
C-Path’s Critical Path to Tuberculosis Drug Regimens (CPTR) initiative has many active and ongoing partnerships with the World Health Organization (WHO). Many members of WHO participate in CPTR as consortium members, and as active members of project teams. Through its relationships with WHO, CPTR has been invited to participate in a number of other initiatives, including European & Developing Countries Clinical Trials Partnership (EDCTP) and Life Prize (formerly the 3P Project). Collaborations and achievements of note include:December 2014 – CPTR partnered with WHO, FIND, Stop TB Partnership’s New Diagnostic Working Group (NDWG), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health to create and implement a Rapid Drug Susceptibility Test Data Platform (later named the Relational Sequencing TB Data Platform, or ReSeqTB). This effort was supported by a multi-year grant from the Bill & Melinda Gates Foundation.April 2016 – In partnership with the Special Programme for Research and Training in Tropical Diseases of WHO (TDR), the TB Alliance, and St. George’s University of London. CPTR launched the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS). This valuable tool provides a wealth of standardized, curated data from the OFLOTUB, REMoxTB, and RIFAQUIN clinical trials, with additional trials expected to be added in the future.
October 2016 – CPTR and the Global TB Programme of the WHO partnered with researchers from the University of California, San Francisco (UCSF), to develop leading-edge quantitative analyses of data from the TB-PACTS database. This collaboration, called TB-ReFLECT, will extract from these analyses key lessons from the TB-PACTS platform, and then package such lessons as tools for future TB trial design.
January 2017 – ReSeqTB, a data-sharing platform and analytic visualization tool that can be used to discover, grade, and track key bacterial drug resistance mutations for TB, is publicly launched. This platform was developed in partnership with WHO, FIND, NDWG, CDC, and NIH.
October 2017 – C-Path, IMI, and TDR/WHO agreed to have C-Path acquire and integrate IMI datasets into the TB-PACTS platform. To date, C-Path has received fully executed Data Contribution Agreements and completed transfer for 12 of the 22 clinical trial data sets in the IMI database.
Ongoing – C-Path and WHO, together with FIND, are pursuing additional funding to support implementation of the ReSeqTB platform to support WHO’s TB surveillance effort.
|Foundation for Innovative New Diagnostics
FIND is an integral collaborator in CPTR and has been a key partner in the creation and continued development of ReSeqTB. Several FIND representatives are active consortium members, and the organization has contributed data to ReSeqTB.Collaborations and achievement of note include:
December 2014 – CPTR partnered with FIND, WHO, Stop TB Partnership’s New Diagnostic Working Group (NDWG), the Centers for Disease Control and Prevention (CDC), and the National Institutes of Health) to create and implement a Rapid Drug Susceptibility Test Data Platform (later named the Relational Sequencing TB Data Platform, or ReSeqTB). This effort was supported by a multi-year grant from the Bill & Melinda Gates Foundation.
January 2017 – ReSeqTB, a data-sharing platform and analytic visualization tool that can be used to discover, grade, and track key bacterial drug resistance mutations for TB, is publicly launched. This platform was developed in partnership with FIND, WHO, NDWG, CDC, and NIH.
Ongoing – C-Path and FIND, together with WHO, are pursuing additional funding to support implementation of the ReSeqTB platform to support WHO’s TB surveillance effort.
|European Federation of Pharmaceutical Industries and Associations
EFPIA represents the pharmaceutical industry operating in Europe, including 33 national associations and 40 pharmaceutical companies. Multiple EFPIA member companies participate in C-Path’s programs, including PSTC’s collaborative research in safety biomarkers, and the T1D Consortium’s work to qualify islet autoimmunity antibodies as prognostic biomarkers for T1D.
Wellcome Trust, a global charitable organization based in the UK, supports research projects in science, population health, medical innovation, the humanities, and social sciences and public engagement. It has sponsored or co-sponsored workshops that included presenters from C-Path’s INC and CPTR.
|European & Developing Countries Clinical Trials Partnership (EDCTP)
C-Path works with EDCTP as a founding partner in the Life Prize effort.
|Medicines Patent Pool (MPP)
C-Path works with MPP as a founding partner in the Life Prize effort.
C-Path is a founding partner in the Life Prize (formerly the 3P Project), a new and innovative financing and enabling framework to incentivize the development of new TB regimens. C-Path is working together with several other non-governmental organizations, medical research councils, civil society representatives, and the South African government on this effort. The Life Prize has the capacity to transform the TB R&D space by encouraging substantially increased levels of research activity, facilitating collaboration for current TB R&D actors, and encouraging new actors to engage in TB R&D activities, while promoting the development of new drug regimens capable of dramatically shortening the treatment for all forms of TB.
|Fraunhofer InstituteC-Path’s CPAD has an MoU with Fraunhofer Institute for Algorithms and Scientific Computing.
C-Path’s INC regularly collaborates with Bliss, a UK-based charity focused on babies who are born premature or sick. Several representatives from Bliss are members of INC’s coordinating committee.
|European Foundation for the Care of Newborn Infants
A consultant to C-Path’s INC, EFCNI is the first pan-European organization that represents the interests of pre-term and newborn infants and their families. Like INC, it brings together healthcare experts and scientists with the goal of improving the long-term health of pre-term infants and newborns with illnesses.